Sildenafil(SDN) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Sildenafil(SDN) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to Drugs of Abuse diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-209-1 | 1. BSA-Sildenafil(SDN) 2. Anti-Sildenafil(SDN) mouse monoclonal antibody | $2709.00 |
GMP-SMT-209-2 | 1. OVA-Sildenafil(SDN) 2. Anti-Sildenafil(SDN) mouse monoclonal antibody | $2709.00 |
GMP-SMT-209-3 | 1. BSA-Sildenafil(SDN) 2. Anti-Sildenafil(SDN) human monoclonal antibody | $2709.00 |
GMP-SMT-209-4 | 1. OVA-Sildenafil(SDN) 2. Anti-Sildenafil(SDN) human monoclonal antibody | $2709.00 |
GMP-SMT-209-Ag-1 | BSA-Sildenafil(SDN) | $756.00 |
GMP-SMT-209-Ag-2 | OVA-Sildenafil(SDN) | $756.00 |
GMP-SMT-209-Ab-1 | Anti-Sildenafil(SDN) mouse monoclonal antibody | $1953.00 |
GMP-SMT-209-Ab-2 | Anti-Sildenafil(SDN) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Sildenafil(SDN)
Cat No. | GMP-SMT-209-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Sildenafil(SDN) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Sildenafil(SDN) had been validated with our anti-Hapten antibody Anti-Sildenafil(SDN) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Sildenafil(SDN)
Cat No. | GMP-SMT-209-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Sildenafil(SDN) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Sildenafil(SDN) had been validated with our anti-Hapten antibody Anti-Sildenafil(SDN) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Sildenafil(SDN) mouse monoclonal antibody
Cat No. | GMP-SMT-209-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.4-0.5 |
Products description | The anti-Hapten antibody against hapten Sildenafil(SDN) had been validated with our hapten hapten-carrier conjugates BSA-Sildenafil(SDN) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Sildenafil(SDN) human monoclonal antibody
Cat No. | GMP-SMT-209-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.4-0.5 |
Products description | The anti-Hapten antibody against hapten Sildenafil(SDN) had been validated with our hapten hapten-carrier conjugates BSA-Sildenafil(SDN) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Biomarker Information
1. Understanding Sildenafil (SDN) and its Significance in In Vitro Diagnosis (IVD)
Sildenafil, often referred to by its chemical shorthand SDN, is a prominent small molecule pharmaceutical compound known for its therapeutic application, with the well-known brand name Viagra in the commercial sphere. Within the realm of in vitro diagnosis (IVD), our biopharmaceutical company offers specialized resources and solutions geared towards the precise characterization and quantification of SDN and its related derivatives.
Role in IVD (Serial Number 1)
The pivotal role that SDN plays in IVD hinges on its ability to facilitate accurate detection and identification within various biological matrices. This role holds particular significance for clinical practitioners, researchers, and healthcare professionals engaged in patient care, pharmacokinetic studies, and the detection of potential misuse.
Our extensive repertoire of anti-Sildenafil antibodies, complemented by a diverse array of small molecule competitive antigens, including Carrier-coupled antigens, immunogens, hapten-carrier conjugates, BSA-conjugated, and OVA-conjugated forms of Sildenafil, empowers IVD experts in the development of highly sensitive immunoassays. These immunoassays include enzyme-linked immunosorbent assays (ELISA) and chemiluminescent assays, which are instrumental in delivering precise and reproducible measurements of Sildenafil concentrations within clinical specimens.
2. The Imperative for Sildenafil (SDN) Quantification (Serial Number 2)
The compelling need for precise quantification of Sildenafil is underscored by several critical factors:
a. Therapeutic Monitoring: Clinicians and healthcare providers require rigorous monitoring of Sildenafil levels among patients under treatment to ascertain the drug's efficacy and safety. Accurate measurements are indispensable for tailoring treatment regimens and making necessary adjustments to achieve the desired clinical outcomes while avoiding potential adverse effects.
b. Pharmacokinetics Profiling: Pharmacokinetics, a fundamental aspect of drug development and usage, necessitates the meticulous quantification of Sildenafil. Researchers rely on this data to elucidate its absorption, distribution, metabolism, and excretion patterns within the human body. This comprehensive understanding serves as the foundation for optimizing dosing strategies and informs the development of novel drug formulations.
c. Misuse Deterrence: Sildenafil is susceptible to recreational misuse, which can lead to detrimental health consequences. The quantification of Sildenafil assumes a critical role in identifying unauthorized usage, particularly among specific demographics such as athletes or individuals at risk of misuse. This proactive approach helps address potential health concerns while also contributing to public health efforts to combat drug misuse.
d. Quality Control: Manufacturers of pharmaceutical products that incorporate Sildenafil must adhere to stringent quality control measures to ensure product potency, consistency, and safety. Routine and thorough assessment of Sildenafil content is a cornerstone of maintaining product quality standards. This is especially crucial given the significance of accurate dosing in pharmaceutical products to achieve the intended therapeutic effects and minimize the risk of adverse events.
In summary, the quantitative evaluation of Sildenafil, facilitated by our portfolio of anti-Sildenafil antibodies and competitive antigens, plays an indispensable role across clinical, investigative, and quality assurance domains. It empowers healthcare professionals, researchers, and pharmaceutical manufacturers with the tools and knowledge needed to ensure accurate detection, precise quantification, and vigilant surveillance of Sildenafil in diverse applications. This, in turn, contributes significantly to enhanced patient care, informed drug development paradigms, and the overarching goals of public health and pharmaceutical quality control.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.